Jennifer Stevens

Jennifer joined TriSalus in March 2021 as Senior Vice President, Pharmaceutical Regulatory Affairs. She brings us expertise in regulatory affairs, law, and policy developed over nearly 30 years of advising clients as a regulatory leader in industry, a regulator at the FDA, and an attorney/partner in several law firms, including Kirkland & Ellis, Willkie, Farr & Gallagher, and Pillsbury, where her work included counseling regulated industry.

Most recently, Jennifer was Executive Director, Immuno-Oncology/Oncology, Global Regulatory Affairs at EMD Serono (Merck KGaA) where she had oversight responsibility for early and late-stage immuno-oncology/oncology assets. Her accomplishments included regulatory approvals globally for Bavencio, an anti-PD1 therapy being developed in collaboration with Merck KGaA/Pfizer, including BLAs/sBLAs (Merkel Cell carcinoma, 2L urothelial carcinoma (UC), Renal Cell carcinoma, and 1L UC maintenance). Her work also included due diligence projects for in-licensing/purchase of early/mid-stage assets.

Before EMD, Jennifer spent 4+ years as Counsel at the FDA, advising on regulations, policy, and agency guidance.

Jennifer received her bachelor’s degree from the University of Illinois and her JD from George Washington University, graduating cum laude from both institutions.